ASND vs INCY
Ascendis Pharma A/S and Incyte, both Healthcare
Incyte is the larger company at $20B against $17B. Over the past year INCY returned +31% against +16% for ASND. The RyuScore puts INCY ahead, 82 against 9 out of 100.
| Figure | ASND | INCY |
|---|---|---|
| Last close | $229 | $113 |
| Market cap | $17B | $20B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 15.9 |
| 1-year return | +16% | +31% |
| 5-year return | +49% | +56% |
| RyuScoresector-relative, 1–10 | 9/100 | 82/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Ascendis Pharma A/S
Revenue of $248M in Q4 2025, net income null.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.